NDAORALCAPSULE, PELLETS
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
51
Data completeness
5/8 — Partial
XALKORI (crizotinib) by Pfizer is cytochrome p450 3a inhibitors [moa]. First approved in 2023.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XALKORI (crizotinib) is an oral kinase inhibitor that blocks cytochrome P450 3A, designed to treat ALK-positive and ROS1-positive non-small cell lung cancer. It works by inhibiting abnormal kinase signaling that drives tumor growth in these genetically-defined patient populations. The drug represents a precision oncology approach targeting specific molecular alterations.
$52MPart D
GrowthGrowing
3.4 years to LOEEarly-stage growth product with moderate Medicare utilization ($52M Part D spend), indicating expanding market adoption and growing commercial infrastructure needs.
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (51)
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Started Dec 2023
190 enrolled
Carcinoma, Non-Small-Cell Lung
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Started Oct 2023
420 enrolled
Metastatic Uveal Melanoma
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
Started Dec 2021
275 enrolled
Non-Small Cell Lung CancerALK-positiveSAF-189s
Crizotinib Continuation Clinical Study
Started Dec 2021
27 enrolled
NSCLCALCLIMT
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Started Sep 2021
220 enrolled
Carcinoma, Non-Small-Cell Lung
Worked on XALKORI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.